Mitochondrial Transplantation: Moving Cellular Powerhouses Between Cells
Key takeaways
- Mitochondrial transplantation means moving intact mitochondria from one cell or tissue into another — a research frontier, not a consumer product or approved treatment.
- Cells appear to swap mitochondria naturally through thin bridges called tunneling nanotubes and through release and uptake of mitochondria (PRECLINICAL, with early human surgical work).
- A small, uncontrolled pediatric cardiac-surgery series injected a patient’s own mitochondria into oxygen-starved heart tissue; researchers reported qualitative improvement but flagged major unanswered questions (HUMAN, pilot).
- Scientists still debate how many transplanted mitochondria actually get inside cells and how long they stay functional.
- Supporting your own mitochondrial quality control — through exercise, sleep, and mitophagy activators like standardized Urolithin A — is the accessible, everyday version of “mitochondrial renewal.”
Few ideas in cell biology sound more like science fiction than moving the cell’s power plants from one place to another. Yet “mitochondrial transplantation” is a real and active area of research, with laboratory experiments and even a handful of early human surgical reports. It is worth understanding what the science actually shows — and, just as importantly, what it does not — because the concept is increasingly used (and sometimes overstated) in longevity conversations.
What is mitochondrial transplantation?
Mitochondria are the organelles that convert the food you eat and the oxygen you breathe into usable chemical energy. When a cell’s mitochondria are damaged — by a loss of blood flow, toxins, or disease — the cell struggles to make enough energy to function. Mitochondrial transplantation is the attempt to fix that at the source: isolate healthy, intact mitochondria and introduce them into the affected cells or tissue.
In practice this has taken several forms in the laboratory, from directly injecting isolated mitochondria into tissue, to co-culturing cells so one population donates mitochondria to another. A detailed overview of how the field moved from animal models toward early human use is laid out in a 2017 review in Mitochondrion, and a more recent summary of mitochondrial transfer technologies catalogs the delivery methods now under study.
How do cells share mitochondria naturally?
The reason researchers think transplantation might work at all is that cells already trade mitochondria on their own. One of the best-described routes is the tunneling nanotube — a thin membrane bridge that temporarily connects two cells and lets cargo, including whole mitochondria, pass between them.
In a frequently cited laboratory study, mesenchymal stem cells transferred mitochondria to immune cells (macrophages) through these nanotubes, which boosted the macrophages’ ability to engulf debris in a model of acute lung injury (PRECLINICAL). You can read that work in PMC. More recent experimental work has explored using engineered nanotube-based transfer to “supercharge” T cells with fresh mitochondria, described in this 2025 report (PRECLINICAL). The takeaway: mitochondrial sharing is a genuine biological phenomenon, which is what makes deliberate transfer plausible.
Has mitochondrial transplantation been done in people?
Yes — but only in very limited, experimental settings, and the evidence is early. The most discussed example is a small pilot series in children who had suffered myocardial ischemia (oxygen starvation of the heart) after cardiac surgery and required mechanical circulatory support.
In that work, surgeons isolated mitochondria from a small sample of each child’s own abdominal muscle — an autologous approach, meaning the mitochondria came from the same patient — and injected them into the injured heart muscle. A procedural description of autologous mitochondrial transplantation for this purpose appears in the Journal of Thoracic and Cardiovascular Surgery (HUMAN, pilot).
A thoughtful critical appraisal published in the Journal of Clinical Investigation summarized the pilot and its limitations: five children were treated, the authors reported qualitative improvement in heart function within days, and most recovered — but there was no control group, assessment was subjective, and the timing differed from the animal experiments the approach was based on. The same appraisal raised pointed mechanistic concerns (HUMAN, with caveats).
What are the biggest unanswered questions?
Even enthusiastic researchers acknowledge that mitochondrial transplantation faces hard scientific hurdles. The critical appraisal above highlighted several:
| Open question | Why it matters |
|---|---|
| Do the mitochondria survive delivery? | Fluid outside cells is high in calcium, which can trigger a “permeability transition” that destroys isolated mitochondria. |
| How many actually get inside cells? | Estimates of roughly 3–7% internalization have been reported — which critics argue is far too few to meaningfully change a cell’s energy output. |
| Can external mitochondria make usable energy? | It is unclear how injected mitochondria would produce ATP and route it to where the cell needs it. |
| Will controlled trials hold up? | Several once-promising cardioprotective strategies failed in rigorous randomized testing. Uncontrolled pilots are a starting point, not proof. |
Laboratory and animal work continues to refine the idea — for example, a 2024 study in Scientific Reports reported that mitochondrial transplantation shifted gene and protein patterns associated with ischemia-reperfusion injury in neonatal animal hearts (PRECLINICAL). But refining a mechanism in the lab is a long way from a proven human therapy.
What does this mean for everyday cellular health?
Here is the honest translation: mitochondrial transplantation is a hospital-and-laboratory research concept aimed at acute, severe tissue injury. It is not something a supplement does, and it is not available as a wellness treatment. Anyone marketing “mitochondrial transplants” for general anti-aging is getting ahead of the evidence.
The accessible version of “mitochondrial renewal” works from a completely different angle. Rather than importing new mitochondria, your cells constantly maintain the ones they have through a quality-control system: they build new mitochondria (biogenesis) and recycle worn-out ones (a process called mitophagy). You can support that system with well-established habits — regular aerobic and resistance exercise, adequate sleep, and not smoking.
Nutrition and certain compounds are studied here too. Standardized Urolithin A, a postbiotic your gut can make from compounds in pomegranates, walnuts, and some berries, has been studied as a mitophagy activator. Early human trials of SOMA Urolithin A gummies’ active ingredient suggest it can influence markers of mitochondrial health and muscle function in adults (HUMAN), while the deeper mitophagy mechanism has been mapped mostly in cell and animal models (PRECLINICAL). This is about helping your cells keep their own power plants in good repair — a structure/function role, not a substitute for the experimental surgical concept above.
Support your cellular health, every day
SOMA delivers a high-potency 1,000 mg dose of Urolithin A in one simple daily gummy — no guesswork, no converter-status lottery.
Shop SOMA Urolithin A Gummies →Frequently asked questions
Is mitochondrial transplantation available as a treatment I can get?
No. It remains experimental and has been used only in limited research and surgical pilot settings. It is not an approved therapy and is not sold as a wellness or anti-aging service.
Is this the same as taking a mitochondrial supplement?
No. Transplantation attempts to physically deliver whole mitochondria into tissue. Supplements like standardized Urolithin A work by a different route — supporting your cells’ own mitophagy and mitochondrial quality control, not transplanting anything.
Do cells really exchange mitochondria on their own?
Yes. Cell-to-cell mitochondrial transfer through tunneling nanotubes and other routes is well documented in laboratory studies, which is part of why deliberate transplantation is being explored.
Could mitochondrial transplantation help with aging someday?
It is far too early to say. Current human work targets acute tissue injury, not general aging, and major questions about mitochondrial survival, uptake, and benefit remain unresolved.
What can I actually do today for mitochondrial health?
Focus on the fundamentals: aerobic and strength exercise, quality sleep, a polyphenol-rich diet, and avoiding smoking. Compounds studied as mitophagy activators, such as Urolithin A, may complement — not replace — those habits.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.